Physician

Omar Al Ustwani, MD

According to 2025 Medicare claims, Omar Ustwani, MD (NPI: 1275769978) practices hematology/oncology in the Vineland, NJ market, with the plurality of this provider's patient population coming from Cumberland, NJ. This provider's primary affiliated billing organization is SOUTHERN ONCOLOGY HEMATOLOGY ASSOC (NPI: 1144211087; TIN: 222182145) and primary practice location at 08360-7059.

Ustwani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 590 traditional Medicare patients, billed 112,598 HCPCS/CPT codes, and received $1,605,335 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,556 prescription claims across 284 beneficiaries totaling $4,628,601 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 13 claims. Open Payments data shows 72 records totaling $1,261. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $527,598 to $1,605,335. Similarly, Part D prescription costs have moved sharply higher in recent years, from $342,611 to $4,628,601. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	593	41,526	$527,598
2016	864	174,069	$1,393,265
2017	754	148,929	$1,398,005
2018	695	147,222	$1,488,286
2019	671	128,691	$1,792,087
2020	623	143,469	$2,086,391
2021	607	121,729	$2,039,724
2022	615	129,834	$2,264,138
2023	596	131,785	$1,917,506
2024	590	112,598	$1,605,335

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	102	460	$342,611
2016	137	746	$704,854
2017	137	707	$813,058
2018	166	868	$1,570,283
2019	195	1,154	$2,245,140
2020	230	1,765	$3,466,478
2021	253	1,447	$2,398,532
2022	296	1,576	$2,910,675
2023	290	1,547	$4,563,939
2024	284	1,556	$4,628,601

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	28	$2,204
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	46	$2,327
2022	N/R	29	$669
2023	N/R	13	$10,844
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	75	203	$114
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	139	270	$111
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	326	543	$73
96372	Injection of drug or substance under skin or into muscle	96	254	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	292	678	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	27	742	$457,737
Keytruda	Pembrolizumab	29	798	$434,059
Venclexta	Venetoclax	25	742	$333,396
Imbruvica	Ibrutinib	13	594	$329,600
Xtandi	Enzalutamide	21	630	$302,654

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	72	$1,261	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Omar Al Ustwani, MD?

Tedicare shows public-source Medicare data for Omar Al Ustwani, MD (NPI 1275769978), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Omar Al Ustwani, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Omar Al Ustwani, MD?

Omar Al Ustwani, MD is linked to SOUTHERN ONCOLOGY HEMATOLOGY ASSOC (billing NPI 1144211087) in the available physician profile data.

Does Omar Al Ustwani, MD have Open Payments data?

Omar Al Ustwani, MD has 72 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.